Mustang Bio Inc at Oppenheimer Fall Healthcare Life Sciences & MedTech Summit (Virtual) Transcript

The following is excerpted from the question-and-answer section of the transcript.

Question: Jacqueline Lu - Oppenheimer & Co. Inc. - Analyst : Thanks, Manny. Let's see if we can field a few questions from the audience. It looks like we don't have any questions from the audience, but I do have a few questions for you. So first, you're expecting to dose the first patient with mass-manufactured MB-107 in 3Q. What are your expectations for the registrational requirements in terms of numbers of patients you have to treat with the drug, and how long you will have to follow them for? And I have the same question for the 207.

Question: Jacqueline Lu - Oppenheimer & Co. Inc. - Analyst : Okay, yes, that makes sense. And my next question is so this year, there has been 50 scares for lentiviral gene therapies, including a case of insertional oncogenesis in one of the bluebird trials, the CALD program. Are you seeing any evidence that the FDA is being more cautious on lentiviral gene therapies in general, which may manifest a longer follow-up requirements or a larger safety database size?

Question: Jacqueline Lu - Oppenheimer & Co. Inc. - Analyst : Okay, yes. That makes sense. That's fair. My last question is do you see the relatively mild safety profile with the 106 asset, primarily as a function of the CD20 target, or it's more due to the design of the CAR construction or something else?

Question: Jacqueline Lu - Oppenheimer & Co. Inc. - Analyst : Okay, thanks for elaborating on that. That's all my questions. I guess that's the end of our Q&A session for today. And I think we're just about out of time. So I think we are expecting more exciting updates later this year and clinical results from some of your academic collaborators as well as the initiation of the pivotal trial for MB-107. Thank you so much for our discussion today, and thanks to everyone in the audience for listening in. I think we can feel free to disconnect now. Thank you so much, everyone.